2011-2021年肾细胞癌免疫治疗研究热点的可视化分析.pdf

CorrespeuateReseari文献研究联勤军事医学2 0 2 3年6 月2 8 日第37 卷第6 期Mil Med Jnt Log,Vol.37,No.6,June28,202351920112 0 2 1年肾细胞癌免疫治疗研究热点的可视化分析陈嘉怡，邵昱玮，党羚榕，单原子，李剑，陈冬玲，侯恩存【摘要】目的通过对近10 年发表的肾细胞癌（renal cell carcinoma，RCC)免疫治疗相关文献进行可视化分析，探讨RCC免疫治疗领域研究进展及趋势。方法检索Webof Science核心合集数据库2 0 112 0 2 1年发布的RCC免疫治疗相关文献，采用CiteSpace5.7.R2软件进行数据可视化分析并绘制热点演进进程。结果共纳人16 8 0 篇文献。发文量最多的国家是美国，其次是中国；发文量最高的机构是德克萨斯大学安德森癌症中心；各作者的发文量差异不明显，美国作者ToniK.Choueiri发文量最多；期刊中新英格兰医学杂志共被引频次最高；涉及的研究方向包括肿瘤微环境（t u m o r m i c r o e n v i r o n m e n t，T M E）、靶向抑制性细胞、靶向代谢途径、免疫治疗不良事件及免疫联合治疗模式等。结论近10 年来RCC免疫治疗的研究发文量逐年增长，探索新型免疫治疗手段及联合不同疗法将成为该领域未来研究的主要趋势。【关键词】肾细胞癌；免疫治疗；可视化分析；文献计量学【中图分类号】R 737.11【文献标识码】1Adoi:10.13730/j.issn.2097-2148.2023.06.014ers of Immunotherapy for Renal Cell Carcinoma from 2011 toRenal Cell Carcinoma from 2011 to 2021:A Visual Analysisch Hotspots and Frontiers of Immunotherapy for Renal Cell CCHEN Jiayi,SHAOYuwei,DANG Lingrong,SHAN Yuanzi,LI Jian,CHEN Dongling,HOU Encun.GradSchool,Guangi University of Chinese Medicine,Nanning Guangri 530000,Chinacom【A b s t r a c t ObjectiveTo visual analyze the literature related to immunotherapy for renal cell carcinoma(RCC)published in the past 10 years through bibliometric analysis,and to explore the research progress and cutting-edge trendsin this field.Methods Literature related to RCC immunotherapy published in Web of Science core collection databasefrom 2011 to 2021 was searched,data visualization analysis was performed by CiteSpace 5.7.R2 software and hotspotevolution process was plotted.Results There were 1680 papers were finally included.The country with the largest num-ber of documents issued was the United States,followed by China;the institution with the highest number of documentsissued was the University of Texas Anderson Cancer Center;there is no significant difference in the number of documentsissued by each author,and Toni K.Choueiri,the American author,had the largest number of documents issued;TheNew England Journal of Medicine had the highest frequency of co-citation in the journal;the research directions in-volved including:tumor microenvironment(TME),targeted inhibitory cells,targeted metabolic pathways,immunothera-py adverse events and immunization combined therapy models.Conclusion In recent 10 years,the number of researchdocuments on immunotherapy for renal cell carcinoma has been increasing year by year,and exploring new immunotherapymethods and combining different therapies will become the main trend of future research in this field.KeywordsRenal cell carcinoma;Immunotherapy;Visual analysis;Bibliometrics肾细胞癌(renal cell carcinoma,RCC)是常见的泌尿系统恶性肿瘤,该病至晚期平均5年生存率较低 1，【基金项目】广西科技计划重点研发计划（桂科AB21196012）【作者单位】530 0 0 0 广西南宁，广西中医药大学研究生院（陈嘉怡、邵昱玮、党羚榕、单原子、李剑、陈冬玲）；广西中医药大学附属瑞康医院肿瘤科（侯恩存）【通信作者】侯恩存，E-mail:约2 0%的RCC患者初诊时已存在远处转移，近30%的术后患者出现复发转移 2 。由于RCC对放、化疗不敏感，靶向药物治疗是近10 年晚期RCC的标准一线治疗，但大部分患者都会产生耐药，疗效不尽如人意 3。免疫治疗作为新型治疗方法，可通过激活患者免疫系统，增强肿瘤微环境下的抗肿瘤免疫力继而抑制并杀伤癌细胞 4。近年来细胞因子疗法、免疫检查Mil Med Jnt Log,Vol.37,No.6,June 28,2023联勤军事医学2 0 2 3年6 月2 8 日第37 卷第6 期520点抑制剂(immune checkpoint inhibitors,ICIs)疗法、肿瘤疫苗等免疫治疗可为晚期RCC患者带来临床获益，已成为RCC治疗的研究新方向。为进一步了解RCC免疫治疗领域的研究现状和发展趋势，对相关文献进行科学归纳总结。CiteSpace是通过绘制知识图谱以显示某一学科领域的研究进展和科研前沿的软件 5。文献计量学及可视化分析可对文献数据进行统计定量分析，以图像形式呈现研究内容，为揭示研究现状、预测未来研究方向提供较为客观的依据。本研究利用文献计量学方法，借助CiteSpace软件对近10 年WOS（W e b o f Sc i e n c e)-SCI Ex p a n d e d 中收录的 RCC免疫治疗相关文献进行可视化分析，以期为该领域临床及科研工作者提供新思路。1资料与方法1.1数据来源计算机检索WOS-SCIExpanded数据库，检索时间设为2 0 11-0 1-0 1/2 0 2 1-12-31日。文献类型：Arti-cle,语种：English，索引:SCI Expanded。共检索到文献2 8 57 篇，剔除非英语、与主题无关、文献类型不符(非研究类、综述类文章)及重复发表文献。具体检索策略:TS=（r e n a l c e l l c a r c i n o m a O R Ca r c i n o m a,Re-nal Cell OR Carcinomas,Renal Cell OR Renal CellCarcinomas OR nephropida Carcinoma OR Carcino-ma,nephropida OR nephropida Carcinomas OR Ade-nocarcinoma Of Kidney OR Adenocarcinoma Of Kid-neys OR Kidney,Adenocarcinoma Of OR Renal CellCarcinoma OR Renal Cell Cancer OR Cancer,RenalCell OR Renal Cell Cancers OR Adenocarcinoma,Renal OR Renal Adenocarcinoma OR Renal Adeno-carcinomas OR Renal Carcinoma OR Carcinoma,Re-nal OR Renal Carcinomas OR Adenocarcinoma,Re-nal Cell OR Adenocarcinomas,Renal Cell OR RenalCell Adenocarcinoma OR Renal Cell Adenocarcino-mas OR Chromophobe Renal Cell Carcinoma OR Sar-comatoid Renal Cell Carcinoma OR Papillary RenalCell Carcinoma OR Renal Cell Carcinoma,PapillaryOR chromophil Renal Cell Carcinoma OR Clear CellRenal Cell Carcinoma OR grawitz Tumor OR Tumor,grawitz OR Clear Cell Renal Carcinoma OR Carcino-ma,hypernephroma OR hypernephroma CarcinomaOR hypernephroma Carcinomas OR HypernephromaOR hypernephroma OR Collecting Duct Carcinoma(Kidney)OR Carcinoma,Collecting Duct(Kidney)OR Carcinomas,Collecting Duct(Kidney)OR Col-lecting Duct Carcinomas（K i d n e y）O R Co l l e c t i n gDuct Carcinoma of the Kidney OR Renal CollectingDuct Carcinoma OR Collecting Duct Carcinoma ORCarcinoma,Collecting Duct OR Carcinomas,Collec-ting Duct OR Collecting Duct Carcinomas)AND TS=(Immunotherapy OR Immunotherapies OR Immu-nity therapy)。1.2研究方法由两名研究者逐条阅读文献题目与摘要并交叉核对，最终纳人16 8 0 篇有效文献，将所有文献